Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
Chee-Seng Tan1, David Gilligan2, Simon Pacey3
1Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore.
Abstract:
Discovery of activating mutations in EGFR and their use as predictive biomarkers to tailor patient therapy with EGFR tyrosine kinase inhibitors (TKIs) has revolutionised treatment of patients with advanced EGFR-mutant non-small-cell lung cancer (NSCLC). At present, first-line treatment with EGFR TKIs (gefitinib, erlotinib, and afatinib) has been approved for patients harbouring exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations. These agents improve response rates, time to progression, and overall survival. Unfortunately, patients develop resistance, limiting patient benefit and posing a challenge to oncologists. Optimum treatment after progression is not clearly defined. A more detailed understanding of the biology of EGFR-mutant NSCLC and the mechanisms of resistance to targeted therapy mean that an era of treatment approaches based on rationally developed drugs or therapeutic strategies has begun. Combination approaches-eg, dual EGFR blockade-to overcome resistance have been trialled and seem to be promising but are potentially limited by toxicity. Third-generation EGFR-mutant-selective TKIs, such as AZD9291 or rociletininb, which target Thr790Met-mutant tumours, the most common mechanism of EGFR TKI resistance, have entered clinical trials, and exciting, albeit preliminary, efficacy data have been reported. In this Review, we summarise the scientific literature and evidence on therapy options after EGFR TKI treatment for patients with NSCLC, aiming to provide a guide to oncologists, and consider how to maximise therapeutic advances in outcomes in this rapidly advancing area.
Insights
Activating mutations in epidermal growth factor receptor (EGFR) guide targeted therapies for non-small cell lung cancer (NSCLC). Resistance to these therapies necessitates exploring novel treatment strategies and next-generation inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Activating mutations in the epidermal growth factor receptor (EGFR) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) using EGFR tyrosine kinase inhibitors (TKIs).
- Current first-line treatments targeting specific EGFR mutations (exon 19 deletions or exon 21 L858R substitution) improve patient outcomes but are often limited by acquired resistance.
- The emergence of resistance mechanisms poses a significant challenge, necessitating the development of alternative and advanced therapeutic strategies.
Purpose of the Study:
- To review current evidence on therapeutic options for patients with EGFR-mutant NSCLC who progress on EGFR TKIs.
- To provide guidance for oncologists on managing treatment resistance in this patient population.
- To explore emerging treatment approaches, including combination therapies and third-generation TKIs, to overcome resistance and improve patient outcomes.
Main Methods:
- Comprehensive review of scientific literature and clinical trial data.
- Analysis of treatment efficacy and resistance mechanisms in EGFR-mutant NSCLC.
- Evaluation of novel therapeutic strategies, including dual EGFR blockade and third-generation TKIs targeting resistance mutations.
Main Results:
- First-generation EGFR TKIs (gefitinib, erlotinib, afatinib) demonstrate efficacy but are associated with acquired resistance.
- Combination therapies show promise in overcoming resistance but may be limited by toxicity.
- Third-generation EGFR TKIs (e.g., AZD9291, rociletininb) targeting the common T790M resistance mutation have shown preliminary efficacy in clinical trials.
Conclusions:
- Understanding EGFR mutation biology and resistance mechanisms is crucial for advancing NSCLC treatment.
- New therapeutic strategies, including next-generation TKIs and combination approaches, are essential to address treatment resistance.
- Continued research and clinical trials are vital to optimize outcomes for patients with EGFR-mutant NSCLC.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:38Mitogens and the Cell Cycle
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...